What is Lifesci Capital’s Estimate for TARS Q1 Earnings?

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) – Stock analysts at Lifesci Capital issued their Q1 2026 EPS estimates for Tarsus Pharmaceuticals in a note issued to investors on Monday, March 16th. Lifesci Capital analyst F. Brisebois forecasts that the company will earn ($0.52) per share for the quarter. Lifesci Capital has a “Strong-Buy” rating on the stock. The consensus estimate for Tarsus Pharmaceuticals’ current full-year earnings is ($3.17) per share. Lifesci Capital also issued estimates for Tarsus Pharmaceuticals’ Q2 2026 earnings at ($0.36) EPS and FY2026 earnings at ($1.01) EPS.

A number of other equities research analysts have also recently commented on the company. The Goldman Sachs Group reissued a “neutral” rating and issued a $68.00 target price on shares of Tarsus Pharmaceuticals in a research note on Thursday, February 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Tarsus Pharmaceuticals in a research report on Thursday, January 22nd. Zacks Research cut shares of Tarsus Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, February 25th. Oppenheimer increased their price objective on shares of Tarsus Pharmaceuticals from $95.00 to $105.00 and gave the company an “outperform” rating in a research report on Wednesday, February 25th. Finally, Mizuho assumed coverage on shares of Tarsus Pharmaceuticals in a report on Thursday, November 20th. They issued an “outperform” rating and a $100.00 target price for the company. Two equities research analysts have rated the stock with a Strong Buy rating, four have issued a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $91.83.

Tarsus Pharmaceuticals Stock Down 2.2%

TARS stock opened at $66.75 on Thursday. The business has a 50 day moving average of $69.36 and a 200 day moving average of $70.18. The firm has a market cap of $2.84 billion, a PE ratio of -41.20 and a beta of 0.55. Tarsus Pharmaceuticals has a twelve month low of $38.51 and a twelve month high of $85.25. The company has a quick ratio of 3.82, a current ratio of 3.85 and a debt-to-equity ratio of 0.21.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Monday, February 23rd. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The business had revenue of $151.67 million for the quarter, compared to analysts’ expectations of $144.56 million. Tarsus Pharmaceuticals had a negative net margin of 14.72% and a negative return on equity of 19.63%.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Hedge funds have recently bought and sold shares of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in shares of Tarsus Pharmaceuticals by 5.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,143 shares of the company’s stock valued at $1,137,000 after acquiring an additional 1,217 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its holdings in shares of Tarsus Pharmaceuticals by 2.0% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 71,220 shares of the company’s stock valued at $3,659,000 after purchasing an additional 1,394 shares during the last quarter. Jane Street Group LLC lifted its position in Tarsus Pharmaceuticals by 105.8% during the first quarter. Jane Street Group LLC now owns 10,456 shares of the company’s stock valued at $537,000 after purchasing an additional 190,000 shares during the period. Envestnet Asset Management Inc. lifted its position in Tarsus Pharmaceuticals by 15.9% during the second quarter. Envestnet Asset Management Inc. now owns 10,356 shares of the company’s stock valued at $420,000 after purchasing an additional 1,418 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Tarsus Pharmaceuticals by 8.0% in the second quarter. Geode Capital Management LLC now owns 934,420 shares of the company’s stock worth $37,859,000 after purchasing an additional 68,986 shares during the last quarter. Hedge funds and other institutional investors own 90.01% of the company’s stock.

Insiders Place Their Bets

In other news, insider Dianne C. Whitfield sold 4,174 shares of the business’s stock in a transaction on Thursday, March 19th. The stock was sold at an average price of $67.00, for a total value of $279,658.00. Following the completion of the transaction, the insider owned 35,028 shares in the company, valued at $2,346,876. The trade was a 10.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CEO Bobak R. Azamian sold 11,964 shares of the company’s stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $67.00, for a total value of $801,588.00. Following the transaction, the chief executive officer directly owned 33,421 shares in the company, valued at approximately $2,239,207. The trade was a 26.36% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders have sold 85,391 shares of company stock worth $5,927,095. 8.97% of the stock is owned by corporate insiders.

Tarsus Pharmaceuticals News Roundup

Here are the key news stories impacting Tarsus Pharmaceuticals this week:

• Positive Sentiment: Lifesci Capital upgraded TARS to “Strong‑Buy” and published a set of 2026 estimates that materially narrow expected losses (FY2026 now seen at -$1.01 vs. broader consensus -$3.17) and forecast a positive Q4‑2026 EPS of $0.09 — a clear bullish catalyst that can support upside expectations. Lifesci upgrade report
• Positive Sentiment: Large institutional investors have been increasing stakes (RTW, Deep Track, Jennison, Vanguard, Morgan Stanley among others), keeping roughly 90% institutional ownership — steady buying from big funds tends to support share-price stability and upside over time. MarketBeat TARS coverage
• Neutral Sentiment: Analyst consensus remains mixed‑to‑favorable: the average recommendation is “Moderate Buy” and some firms (Guggenheim, Oppenheimer) have raised targets while others are more cautious — this keeps the outlook constructive but not unanimous. Analyst consensus article
• Neutral Sentiment: Recent quarterly results: revenue beat estimates ($151.7M vs. $144.6M) but EPS slightly missed ($0.20 loss vs. $0.19 expected). Revenue strength is supportive; continued negative margins and guidance keep risk elevated until pipeline milestones materialize. Earnings summary
• Negative Sentiment: Insider selling: Director William J. Link sold 12,500 shares at an average $68.79 on March 16 (disclosed via SEC filing), reducing his stake by ~9.7%. Insider sales can create short‑term downward pressure or be interpreted by some investors as profit‑taking. InsiderTrades report (SEC Form 4)

About Tarsus Pharmaceuticals

Tarsus Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for diseases of the eye and ocular surface. The company’s research platform centers on neuro‐effector modulation to address underlying disease mechanisms rather than solely treating symptoms. Tarsus’s lead candidate, OC-01 (varenicline solution), is an intranasal formulation in Phase 3 development for the treatment of dry eye disease, a condition affecting millions worldwide and associated with significant patient discomfort and reduced quality of life.

In addition to its dry eye program, Tarsus is advancing preclinical and early‐stage programs targeting other ophthalmic indications, including allergic conjunctivitis and retinal disorders.